HP
GLUE icon

Hound Partners’s Monte Rosa Therapeutics GLUE Stock Holding History

Hound Partners’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-49,995
Closed -$1.14M – 216
2021
Q2 		$1.14M Buy
+49,995
New +$1.02M 0.05% 134

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hound Partners's GLUE Position: Q3 2021 in Review

Hound Partners sold out of Monte Rosa Therapeutics (GLUE) in Q3 2021, closing a stake of 49,995 shares — an estimated $1.14M sold.

Hound Partners first reported a position in GLUE in Q2 2021 and held it in 1 quarter. The position peaked at $1.14M in Q2 2021. 56 funds tracked by Wall St. Rank hold GLUE as of Q3 2021.

  • Hound Partners reported no remaining Monte Rosa Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Hound Partners sold 49,995 Monte Rosa Therapeutics shares in Q3 2021, an estimated $1.14M.
  • Hound Partners first reported a position in Monte Rosa Therapeutics in Q2 2021 and held it in 1 quarter.
  • Hound Partners's Monte Rosa Therapeutics position peaked at $1.14M in Q2 2021.
  • 56 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2021.

Based on Hound Partners's 13F filing for Q3 2021, filed 15 Nov 2021.